NORMOCARB HF 25
LOE Approachingmagnesium chloride; sodium bicarbonate; sodium chloride
NDAINJECTIONSOLUTION
Approved
Jul 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORMOCARB HF 25 is an injectable solution containing magnesium chloride, sodium bicarbonate, and sodium chloride—a balanced electrolyte and buffer formulation. It is used to correct electrolyte imbalances and acid-base disturbances in parenteral nutrition and critical care settings. The combination provides essential ions and buffering capacity to maintain physiologic pH and electrolyte homeostasis.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential downsizing or transition of the brand team in coming years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORMOCARB HF 25 offers exposure to a mature, stable product with limited growth upside but predictable commercial operations. Roles focus primarily on maintaining market share, cost management, and execution rather than innovation or expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.